ESPE Abstracts

Background: The UK has the highest number of children and young people with type 1 diabetes mellitus in Europe, but the lowest number of children and young people attaining good diabetes control.Methods: In December 2012, our diabetes service established the use of an electronic diabetes information management system that was web-based (Twinkle.Net) and routine uploading of glucose meters and pumps (Diasend). The electronic management system Twinkle.Net ...

Background: Prevalence of being overweight or obese is increasing in type 1 diabetes mellitus (T1DM). The recent UK National Paediatric Diabetes Audit (NPDA) 2013/14 reported that 36.6% of 0–11 year old children and 43.9% of 12 years and older children are currently overweight or obese. Childhood obesity in T1DM predicts long-term risk of adult diabetes complications. Previous studies have shown significant positive correlation between HbA1c and total insulin requirement ...

Background: Hypoparathyroidism is usually treated with calcium and vitamin D analogues. Replacing the deficient hormone using recombinant human parathormone Teriparatide (rhPTH) has not yet become a common practice. We report a 3-year-old boy with hypoparathyroidism-deafness-renal dysplasia (HDR) syndrome who has been successfully treated with Teriparatide (1–34 rhPTH), who to our knowledge is only the second child reported in the literature to be successfully treated wit...

Background: Bisphosphonates inhibit osteoclast activity, decreasing bone resorption and increasing bone mineral density (BMD). A Cochrane review in 2007 concluded further evidence is required for use of bisphosphonates in children with secondary osteoporosis.Objective and hypotheses: We appraised our current practice of bisphosphonate use in children with secondary osteoporosis (as defined by the 2013 International Society for Clinical Densitometry Posit...

Puberty is a critical period for the development and acceleration of vascular complications in Type 1 diabetes (T1D). We have shown that metformin in addition to insulin improves vascular smooth muscle function and HbA1c in T1D children over 12 months (1). We aimed to determine if children with T1D who received metformin in a randomized controlled trial (RCT) [Trial registration ACTRN126110001148976] have a sustained vascular function improvement 3 years after ceasing metformi...